Zobrazeno 1 - 10
of 207
pro vyhledávání: '"Spyratos, D."'
Autor:
Mountzios G, Lampaki S, Koliou GA, Vozikis A, Kontogiorgos I, Papantoniou P, Koufaki MI, Res E, Boutis A, Christopoulou A, Pastelli N, Grivas A, Aravantinos G, Lalla E, Oikonomopoulos G, Koumarianou A, Spyratos D, Bafaloukos Snr D, Rigakos G, Papakotoulas P, Fountzilas G, Linardou H
Publikováno v:
Lung Cancer: Targets and Therapy, Vol Volume 12, Pp 93-102 (2021)
Giannis Mountzios,1 Sofia Lampaki,2 Georgia-Angeliki Koliou,3 Athanassios Vozikis,4 Ioannis Kontogiorgos,4 Panagiotis Papantoniou,4 Margarita-Ioanna Koufaki,4 Eleni Res,5 Anastasios Boutis,6 Athina Christopoulou,7 Nicoleta Pastelli,8 Anastasios Griva
Externí odkaz:
https://doaj.org/article/6a71618649294982a297524620b76668
Publikováno v:
Lung Cancer: Targets and Therapy, Vol Volume 8, Pp 101-107 (2017)
Dionisios Spyratos, Eleni Papadaki, Sofia Lampaki, Theodoros Kontakiotis Pulmonary Department, Lung Cancer Oncology Unit, Aristotle University of Thessaloniki, G. Papanicolaou Hospital, Thessaloniki, Greece Abstract: Chronic obstructive pulmonary dis
Externí odkaz:
https://doaj.org/article/c4e5e5ca53924b9f9ac15b74495c7e74
Autor:
Spyratos D, Sichletidis L
Publikováno v:
Therapeutics and Clinical Risk Management, Vol 2015, Iss default, Pp 481-487 (2015)
Dionisios Spyratos, Lazaros Sichletidis Pulmonary Department, “G Papanikolaou” Hospital, Aristotle University of Thessaloniki, Exohi, Thessaloniki, Greece Abstract: Chronic obstructive pulmonary disease (COPD) is a common disease among the elderl
Externí odkaz:
https://doaj.org/article/8dc591852c7d42c4ad385e4cbf1d07d4
Autor:
Zarogoulidis P, Kioumis I, Lampaki S, Organtzis J, Porpodis K, Spyratos D, Pitsiou G, Petridis D, Pataka A, Huang H, Li Q, Yarmus L, Hohenforst-Schmidt W, Pezirkianidis N, Zarogoulidis K
Publikováno v:
Drug Design, Development and Therapy, Vol 2014, Iss default, Pp 1065-1072 (2014)
Paul Zarogoulidis,1 Ioannis Kioumis,1 Sofia Lampaki,1 John Organtzis,1 Konstantinos Porpodis,1 Dionysios Spyratos,1 Georgia Pitsiou,1 Dimitris Petridis,2 Athanasia Pataka,1 Haidong Huang,3 Qiang Li,3 Lonny Yarmus,4 Wolfgang Hohenforst-Schmidt,5 Nikol
Externí odkaz:
https://doaj.org/article/235d916afd8a44488638bfbc363f9117
Autor:
Petridis D, Zarogoulidis P, Kallianos A, Kioumis I, Trakada G, Spyratos D, Papaiwannou A, Porpodis K, Huang H, Rapti A, Hohenforst-Schmidt W, Zarogoulidis K
Publikováno v:
Therapeutics and Clinical Risk Management, Vol 2014, Iss default, Pp 77-86 (2014)
Dimitris Petridis,1 Paul Zarogoulidis,2,3 Anastasios Kallianos,4 Ioannis Kioumis,2 Georgia Trakada,5 Dionysios Spyratos,2 Antonis Papaiwannou,2 Konstantinos Porpodis,2 Haidong Huang,6 Aggeliki Rapti,4 Wolfgang Hohenforst-Schmidt,7 Konstantinos Zarogo
Externí odkaz:
https://doaj.org/article/48bc4406f5e348ae9ba4f47a84713afe
Autor:
Zarogoulidis P, Kioumis I, Porpodis K, Spyratos D, Tsakiridis K, Huang H, Li Q, Turner JF, Browning R, Hohenforst-Schmidt W, Zarogoulidis K
Publikováno v:
Drug Design, Development and Therapy, Vol 2013, Iss default, Pp 1115-1134 (2013)
Paul Zarogoulidis,1,2 Ioannis Kioumis,1 Konstantinos Porpodis,1 Dionysios Spyratos,1 Kosmas Tsakiridis,3 Haidong Huang,4 Qiang Li,4 J Francis Turner,5 Robert Browning,6 Wolfgang Hohenforst-Schmidt,7 Konstantinos Zarogoulidis1 1Pulmonary Department, G
Externí odkaz:
https://doaj.org/article/b23adb0b946d42208b74820952698349
Autor:
Huang H, Porpodis K, Zarogoulidis P, Domvri K, Giouleka P, Papaiwannou A, Primikyri S, Mylonaki E, Spyratos D, Hohenforst-Schmidt W, Kioumis I, Zarogoulidis K
Publikováno v:
Drug Design, Development and Therapy, Vol 2013, Iss default, Pp 1003-1013 (2013)
Haidong Huang,1 Konstantinos Porpodis,2 Paul Zarogoulidis,2,3 Kalliopi Domvri,2 Paschalina Giouleka,2 Antonis Papaiwannou,2 Stella Primikyri,2 Efi Mylonaki,2 Dionysis Spyratos,2 Wolfgang Hohenforst-Schmidt,4 Ioannis Kioumis,2 Konstantinos Zarogoulidi
Externí odkaz:
https://doaj.org/article/153c218f55ff4c1a914ec30fa5a2c0db
Autor:
Hohenforst-Schmidt W, Zarogoulidis P, Darwiche K, Vogl T, Goldberg EP, Huang H, Simoff M, Li Q, Browning R, Turner FJ, Le Pivert P, Spyratos D, Zarogoulidis K, Celikoglu SI, Celikoglu F, Brachmann J
Publikováno v:
Drug Design, Development and Therapy, Vol 2013, Iss default, Pp 571-583 (2013)
Wolfgang Hohenforst-Schmidt,1 Paul Zarogoulidis,2,3 Kaid Darwiche,3 Thomas Vogl,4 Eugene P Goldberg,5 Haidong Huang,6 Michael Simoff,7 Qiang Li,6 Robert Browning,8 J Francis Turner,9 Patrick Le Pivert,10 Dionysios Spyratos,2 Konstantinos Zarogoulidis
Externí odkaz:
https://doaj.org/article/07b6763505f845159b268deb635cb9c5
Background: Data on the safety and efficacy of immune checkpoint inhibitors (ICI) in patients with concurrent autoimmune diseases (AID) are limited. Methods: We performed a retrospective multicenter review of medical records of patients with cancer a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______2127::60b68396854ba135951a4a2886c6c74c
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:2999633
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:2999633
Purpose: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are the preferred first-line option for patients with advanced, EGFR-mutant non-small cell lung cancer (NSCLC). Afatinib, a second-generation irreversible EGFR-TKI, ha
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______2127::8d1170e1561e5624975a5832e29d2e7b
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3103031
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3103031